Featuring perspectives from Drs Sagar Lonial and Krina K Patel.
TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).
OVERVIEW OF ACTIVITY
MM is a plasma cell neoplasm that accounts for approximately 12% of all hematologic cancers and carries with it one of the worst ratios of death to new cases. Although MM will represent only 1.8% of all new cancer cases diagnosed in the United States in 2020, practicing clinicians would be hard pressed to identify an area of oncology in which the research database — and available treatments — has evolved more rapidly over the past decade. In addition, novel agents, including proteasome inhibitors, immunomodulatory agents and Bruton tyrosine kinase inhibitors, have significantly altered the natural history of MM.
To bridge the gap between research and patient care, this program produced in partnership with the University of South Florida (USF Health) Office of Continuing Professional Development features a presentation by and one-on-one interview with a leading hematology-oncology investigator exploring clinical research, published data sets and ongoing trials in addition to a review of the results of a comprehensive web-based survey consisting of case-based and practical management questions regarding the optimal clinical care of patients with MM. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.
LEARNING OBJECTIVES
COMPETENCIES TO BE ADDRESSED
Patient Care and Procedural Skills and Medical Knowledge.
CONTACT INFORMATION
If you have questions regarding credit, please contact cpdsupport@usf.edu.
ACCREDITATION STATEMENT
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
Sagar Lonial, MD
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Takeda Oncology; Contracted Research: Celgene Corporation, Janssen Biotech Inc, Takeda Oncology.
Krina K Patel, MD, MSc
Associate Professor
Center Medical Director
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Nektar, Precision BioSciences, Takeda Oncology; Consulting Agreement: Pfizer Inc; Contracted Research: AbbVie Inc, Allogene Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Cellectis, Janssen Biotech Inc, Nektar, Poseida Therapeutics, Precision BioSciences, Takeda Oncology.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
USF HEALTH CPD STAFF AND RESEARCH TO PRACTICE CME PLANNING COMMITTEE — Members, Staff, and Reviewers have no relevant conflicts to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from AbbVie Inc, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Sanofi Genzyme.
Release date: April 2021
Expiration date: April 2022
(WIFI is recommended for best performance):